Reference
1. Anwanwan D, Singh SK, Singh S, Saikam V, Singh R. Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta BBA - Rev Cancer. 2020;1873(1):188314.
2. Geisler AN, Phillips GS, Barrios DM, et al. Immune checkpoint inhibitor–related dermatologic adverse events. J Am Acad Dermatol . 2020;83(5):1255-1268.
3. Xie C, Zhou X, Liang C, et al. Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer. J Exp Clin Cancer Res . 2021;40(1):266.
4. Massey PR, Okman JS, Wilkerson J, Cowen EW. Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature. Support Care Cancer. 2015 Jun;23(6):1827-35.
5. Zheng Q, Ma Y, Shen F, et al. Case of bullous pemphigoid induced by apatinib mesylate. Br J Clin Pharmacol . 2021;87(4):2158-2159.
6. Chu CY, Chen KY, Wen-Cheng Chang J, Wei YF, Lee CH, Wang WM. Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities. J Formos Med Assoc. 2017 Jun;116(6):413-423.
7. Geisler AN, Phillips GS, Barrios DM, Wu J, Leung DYM, Moy AP, Kern JA, Lacouture ME. Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol. 2020 Nov;83(5):1255-1268.
8. Wang J, Huang D, Yang W, et al. The efficacy and safety of Apatinib in the treatment of advanced non-small cell lung cancer: A retrospective trial. Front Oncol . 2022;12:1030798.
9. Xia H, Zhou C, Luo Z, Zhang P, Zhu L, Gong Z. Apatinib-Induced Hand–Foot Skin Reaction in Chinese Patients With Liver Cancer.Front Oncol . 2021;11:624369.
10. Liao Z, Li F, Zhang C, et al. Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety. Exp Mol Med . 2019;51(3):1-11.
11. Paolino G, Didona D, Magliulo G, et al. Paraneoplastic Pemphigus: Insight into the Autoimmune Pathogenesis, Clinical Features and Therapy.Int J Mol Sci . 2017;18(12):2532. doi:10.3390/ijms18122532
12. Montagnon CM, Tolkachjov SN, Murrell DF, Camilleri MJ, Lehman JS. Subepithelial autoimmune blistering dermatoses: Clinical features and diagnosis. J Am Acad Dermatol . 2021;85(1):1-14.
13. Wakelin, Allen, Zhou, Wojnarowska. Drug‐induced linear IgA disease with antibodies to collagen VII. Br J Dermatol . 1998;138(2):310-314.
14. Montagnon CM, Lehman JS, Murrell DF, Camilleri MJ, Tolkachjov SN. Subepithelial autoimmune bullous dermatoses disease activity assessment and therapy. J Am Acad Dermatol . 2021;85(1):18-27.